Skip to Content

The Potential for Intermediate Clinical Endpoints as Surrogates for Overall Survival

Renee Maria Saliby, a research fellow at Dana-Farber Cancer Institute, presented research exploring the use of intermediate clinical endpoints as surrogates for overall survival in patients with metastatic renal cell carcinoma receiving immune checkpoint-based regimens.

Renee Maria Saliby

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top